Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson’s disease

@article{Ding2007Chronic3T,
  title={Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson’s disease},
  author={Yunmin Ding and Jacqueline Restrepo and Lisa A. Won and Dong-Youn Hwang and Un Jung Kang},
  journal={Neurobiology of Disease},
  year={2007},
  volume={27},
  pages={11-23}
}
L-DOPA-induced dyskinesia (LID) is one of the main limitations of long term L-DOPA use in Parkinson's disease (PD) patients. We show that chronic L-DOPA treatment induces novel dyskinetic behaviors in aphakia mouse with selective nigrostriatal deficit mimicking PD. The stereotypical abnormal involuntary movements were induced by dopamine receptor agonists and attenuated by antidyskinetic agents. The development of LID was accompanied by preprodynorphin and preproenkephalin expression changes in… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 31 CITATIONS

Striatal But Not Extrastriatal Dopamine Receptors Are Critical to Dopaminergic Motor Stimulation

  • Front. Pharmacol.
  • 2017
VIEW 4 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Effects of a combination treatment of KD5040 and L-dopa in a mouse model of Parkinson’s disease

  • BMC complementary and alternative medicine
  • 2017
VIEW 1 EXCERPT
CITES METHODS

References

Publications referenced by this paper.
SHOWING 1-10 OF 70 REFERENCES

A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia.

  • The Journal of neuroscience : the official journal of the Society for Neuroscience
  • 2006
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…